Please provide your email address to receive an email when new articles are posted on . The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate ...
"Randy embodies exactly what the Goodes Prize was established to recognize: science that changes the trajectory of the field," said Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF.
NEW YORK, March 17, 2026 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced the launch of the third phase of its Diagnostics Accelerator (DxA), backed by an additional ...
NEW YORK, NY (July 15, 2020) - A study supported by the Alzheimer's Drug Discovery Foundation and published today in JAMA Network Open provides the first evidence that rotigotine, a drug that acts on ...
The gold-standard dataset will power a new generation of AI tools to forecast Alzheimer's risk, track progression, and guide interventions before symptoms appear NEW YORK, Sept. 30, 2025 /PRNewswire/ ...
The Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, ...
San Francisco, CA (November 30, 2022) – The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal ...
Please provide your email address to receive an email when new articles are posted on . A Canadian neuroimaging company has received an investment from the Alzheimer’s Drug Discovery Foundation to ...
The Frontier Awards are the most prestigious ones and are regarded as the "Oscars" of the Duty Free industry. The award was given to the ADDF during the 19th Tax Free World Exhibition, held in Cannes ...
The Alzheimer’s Drug Discovery Foundation, formed 25 years ago in honor of cosmetic business tycoon Estée Lauder, just received $200 million from the Lauder family—the nonprofit’s largest donation ...
On Thursday, April 7, the Centers for Medicare and Medicaid (CMS) formalized its plan to cover the anti-amyloid drug Aduhelm only for patients enrolled in clinical trials. However, in response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results